ArticleBlood cancer journal2023

Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib.

Chung H Kok et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.